Related Experiment Video

Updated: Jun 22, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.9K

MAPK4 facilitates angiogenesis by inhibiting the ERK pathway in non-small cell lung cancer

Jing Chen1,2, Jing Yang1,2, Yufang Liu1,2

  • 1Special Key Laboratory of Gene Detection & Therapy of Guizhou Province Zunyi Guizhou China.

Cancer Innovation
|July 1, 2024
PubMed
Abstract

Insights

Mitogen-activated protein kinase 4 (MAPK4) promotes non-small cell lung cancer (NSCLC) angiogenesis. Silencing MAPK4 inhibits tumor growth and may offer a new therapeutic target for NSCLC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Angiogenesis is crucial for non-small cell lung cancer (NSCLC) development.
  • The role of atypical mitogen-activated protein kinase 4 (MAPK4) in NSCLC tumor angiogenesis is not well understood.

Purpose of the Study:

  • To investigate the role of MAPK4 in NSCLC angiogenesis.
  • To explore MAPK4 as a potential therapeutic target for NSCLC.

Main Methods:

  • Mice models and human umbilical vein endothelial cells (HUVECs) were used.
  • MAPK4 expression and its effects on cell proliferation, migration, and angiogenesis-related pathways were analyzed.
  • Western blot, immunofluorescence, and flow cytometry were employed.

Main Results:

  • MAPK4 expression in endothelial cells correlated with NSCLC tumor angiogenesis.
  • MAPK4 silencing inhibited HUVEC proliferation and migration, affecting cell cycle and angiogenesis pathways.
  • Higher MAPK4 and CD34 expression indicated poor prognosis in NSCLC patients.

Conclusions:

  • MAPK4 plays a significant role in NSCLC angiogenesis and development.
  • Targeted silencing of MAPK4 effectively inhibited tumor growth in vivo.
  • MAPK4 presents a promising new therapeutic target for NSCLC.
Keywords:
MAPK4NSCLCangiogenesisendothelial cellp‐ERK1/2

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

73
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.6K

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.4K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.5K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K